Fresenius Medical Care AG issues announcement under German Securities Trading Act

Fresenius Medical Care AG, a global provider of products and services for individuals with renal diseases, has issued a regulatory announcement. This notification complies with Article 40, Section 1 of the German Securities Trading Act (WpHG) and is designated for distribution across Europe.

The announcement fulfills a legal requirement for publicly traded companies in Germany. While the specific content of the release is not detailed in the initial filing, such announcements typically pertain to significant corporate developments or information relevant to investors.

Fresenius Medical Care operates in the healthcare sector, focusing primarily on dialysis treatments and related technologies. The company offers a comprehensive range of products and services aimed at improving the quality of life for kidney patients worldwide.

Further details regarding the announcement and its implications are expected to be provided through the company's official communication channels.